Compare iShares Core US Aggregate Bond ETF (AGG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core US Aggregate Bond ETF vs TG Therapeutics Inc — how do they compare? iShares Core US Aggregate Bond ETF trades at $97.51, while TG Therapeutics Inc trades at $49.72 (market cap $7.64B). The key difference: TG Therapeutics Inc is trading nearer its 52-week high, iShares Core US Aggregate Bond ETF nearer its low. Which is the better fit depends on your goals.
| AGG | TGTX | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $101.40 | $59.06 |
52-Week Low | $97.24 | $26.94 |
Market Cap | — | $7.64B |
Enterprise Value | — | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGG trades at $97.505, up 0.27% on the day, with a bearish technical signal from moving averages and neutral oscillators. Recent news highlights institutional activity, including Bay Colony Advisory reducing holdings and First Bank & Trust increasing its stake. Bond ETF flows remain strong, with $300 billion in H1 2026 inflows, but rising Treasury yields and inflation concerns pressure fixed-income assets.
The outlook is cautious due to bearish technicals and macroeconomic headwinds like higher yields and oil prices. Risks include Fed rate hike expectations and Middle East tensions, but AGG offers steady dividends and remains a core holding for income-focused portfolios amid market volatility.
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core US Aggregate Bond ETF
AGG tracks the Bloomberg U.S. Aggregate Bond Index, providing broad exposure to the total U.S. investment-grade bond market. It serves as a core portfolio building block by diversifying across Treasuries, government-related bonds, corporate debt, and mortgage-backed securities.
Read more on AGG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
